Gamida Cel/GMDA

$0.38

-1.03%
-
1D1W1MYTD1YMAX

About Gamida Cel

Gamida Cell Ltd is an Israel-based clinical-stage biopharmaceutical company. The Company develops cell therapies that are designed to cure cancer and rare, serious hematologic diseases. The Company is leveraging its nicotinamide (NAM)-based cell expansion technology toto expand multiple cell types including stem cells and natural killer (NK) cells while maintaining their original phenotype and potency. The following are the Company's clinical pipeline products: Omidubicel dedicated to hematologic malignancies and severe aplastic anemia; GDA-201 dedicated for treatment of non-Hodgkin Lymphoma; GDA-301, GDA-401, GDA-501 dedicated to treatment of solid tumors, GDA-601 dedicated to multiple myeloma.

Ticker

GMDA

Sector

Tervishoid

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Abigail Jenkins

Employees

143

Headquarters

Jerusalem, Israel

Gamida Cel Metrics

BasicAdvanced
$44.85M
Market cap
-
P/E ratio
-$0.89
EPS
1.02
Beta
-
Dividend rate

What the Analysts think about Gamida Cel

Analyst Ratings

Majority rating from 4 analysts.
Buy

Price Targets

Average projection from 3 analysts.
1,039.47% upside
High $6.00
Low $2.00
$0.38
Current price
$4.33
Average price target

Gamida Cel Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-250% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
$600K
∞%
Net income
$-1.5M
-95.25%
Profit margin
-250%
-∞%

Gamida Cel Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 94.07%
QuarterlyAnnual
Q4 22
Q1 23
Q2 23
Q3 23
Q4 23
Actual
-$0.30
-$0.27
-$0.31
-$0.01
-
Expected
-$0.25
-$0.27
-$0.19
-$0.17
-$0.15
Surprise
20%
-1.53%
59.59%
-94.07%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell Gamida Cel stock

Buy or sell Gamida Cel stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing